Bryant Furlow

Contributing Writer https://www.cancertherapyadvisor.com

Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.

Lung Cancer

Recent Advances Offer Paths Forward for Developing Predictive Biomarkers in Cancer Immunotherapy

Bryant Furlow

September 4, 2019

Recent advances in predictive biomarker development clarify how best to determine PD-L1 expression in tumor cells.

Lung Cancer

Upfront Next-Generation Sequencing for Lung Cancer: Can It Save Time and Money?

Bryant Furlow

July 3, 2019

Upfront NGS saves time and money compared with the sequential use of individual gene tests for patients with metastatic lung cancer, according to study authors.

Renal Cell Carcinoma

IL-2 and Metastatic Renal Cell Carcinoma

Bryant Furlow

May 31, 2019

Despite a challenging toxicity profile, high dose interleukin-2 (HD IL-2), one of the earliest-approved immunotherapies for metastatic renal cell carcinoma still has a role in treating selected patients, a new registry analysis shows.

Basket trials are those that test investigational therapies in patients who have different types of cancer but share a particular genomic aberration.

General Oncology

Wider Use of Basket Trials Could Hasten Development of Precision Therapies

Bryant Furlow

April 23, 2019

Basket trials are those that test investigational therapies in patients who have different types of cancer but share a particular genomic aberration.

In patients with completely resected high-risk stage 3 melanoma, adjuvant ipilimumab significantly i

General Oncology

Predicting PD-1/PD-L1 Immunotherapy Responses

Bryant Furlow

March 6, 2019

Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.

Artificial intelligence techniques are being employed to build complex new multivariate prognostic m

Skin Cancer

Dysfunctional CD8+ T Cells Remain Active in Melanoma Tumor Microenvironment

Bryant Furlow

February 28, 2019

Many CD8+ T cells in the melanoma microenvironment are becoming progressively dysfunctional yet remain highly proliferative, according to researchers.

Researchers proposed lowering the circulating plasma cell threshold from 20% to 5% for plasma cell l

Hematologic Cancers, Multiple Myeloma

clonoSEQ and MRD Testing in Multiple Myeloma and ALL

Bryant Furlow

February 27, 2019

Medicare coverage has been announced for Adaptive Biotechnologies’ clonoSEQ® next-generation sequencing assay for the detection of minimal residual disease (MRD) after treatment for multiple myeloma or B-cell acute lymphoblastic leukemia (ALL) — a key step toward its use for patient care in cancer clinics in the United States.1,2The FDA announced regulatory approval for the assay…

“People have shown that the variant-identification quality of WGS is superior to WES,” said Dr Gerst

General Oncology

Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing

Bryant Furlow

February 13, 2019

“People have shown that the variant-identification quality of WGS is superior to WES,” said Dr Gerstein.

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in can

General Oncology

Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves

Bryant Furlow

February 11, 2019

Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field.

Inhibition of ER translocation prevented both ERK reactivation and autophagy, suggesting a potential

Skin Cancer

A Common Factor Links Mechanisms of Acquired Resistance to Melanoma Treatment

Bryant Furlow

February 1, 2019

Inhibition of ER translocation prevented both ERK reactivation and autophagy, suggesting a potential strategy for improving BRAF and MEK inhibition therapy outcomes.

Next post in Skin Cancer